Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AIDS Malignancy Consortium
With
National Cancer Institute (NCI)
The Emmes Company, LLC
University of Arkansas
PRIMARY OBJECTIVES:
I. To identify participant-level factors affecting recruitment of potentially eligible participants in AIDS Malignancy Clinical Trials Consortium (AMC) studies at core and affiliated sites.
SECONDARY OBJECTIVES:
I. To describe the socio-demographic characteristics for participation and non-participation in AMC clinical trials among all approached volunteers across AMC sites.
II. To characterize socio-demographic characteristics with motivation and decision making among those who consented to participate in an AMC trial.
III. To identify the perceived barriers associated with clinical trial participation among those who did not consent to participate in an AMC clinical trial.
IV. To better understand how potential study volunteers learn about AMC clinical trials and by what means are they referred to a particular study.
OUTLINE:
Participants complete the Improving Participation in AMC Clinical Trials (IMPACTS) survey comprising questions about socio-demographic information and clinical trial participation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HIV-infected participants
Cancer or anal dysplasia diagnosis
Offered informed consent on an AMC interventional clinical trial
Ability to understand and the willingness to sign a written informed consent document
You may not be if
Inability to provide informed consent
Clareo Health | Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials